IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,236 | +14.2% | 91,614 | +1.8% | 0.01% | +25.0% |
| Q2 2023 | $3,710 | -35.2% | 90,000 | -45.5% | 0.01% | -42.9% |
| Q1 2023 | $5,723 | +0.4% | 165,000 | +7.8% | 0.01% | -6.7% |
| Q4 2022 | $5,699 | -99.9% | 153,000 | +22.6% | 0.02% | -6.2% |
| Q3 2022 | $5,499,000 | +18.2% | 124,776 | 0.0% | 0.02% | +14.3% |
| Q2 2022 | $4,653,000 | +4.5% | 124,776 | 0.0% | 0.01% | +27.3% |
| Q1 2022 | $4,453,000 | +33.0% | 124,776 | +14.0% | 0.01% | +37.5% |
| Q4 2021 | $3,347,000 | -7.4% | 109,476 | +1.8% | 0.01% | -20.0% |
| Q3 2021 | $3,614,000 | -15.3% | 107,576 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $4,265,000 | -18.6% | 107,576 | -8.4% | 0.01% | -29.4% |
| Q1 2021 | $5,241,000 | -21.0% | 117,395 | +1.1% | 0.02% | -32.0% |
| Q4 2020 | $6,630,000 | +26.3% | 116,150 | +6.0% | 0.02% | +8.7% |
| Q3 2020 | $5,249,000 | +1002.7% | 109,556 | +1256.2% | 0.02% | +666.7% |
| Q2 2020 | $476,000 | +26.6% | 8,078 | +2.3% | 0.00% | 0.0% |
| Q1 2020 | $376,000 | -23.1% | 7,899 | -3.6% | 0.00% | 0.0% |
| Q4 2019 | $489,000 | -90.9% | 8,190 | -90.1% | 0.00% | -88.9% |
| Q2 2019 | $5,383,000 | -15.9% | 82,781 | -40.0% | 0.03% | -28.9% |
| Q1 2019 | $6,402,000 | +70.5% | 137,876 | +95.1% | 0.04% | +52.0% |
| Q4 2018 | $3,754,000 | -41.4% | 70,676 | -48.7% | 0.02% | -34.2% |
| Q3 2018 | $6,402,000 | +783.0% | 137,876 | +698.1% | 0.04% | +660.0% |
| Q2 2018 | $725,000 | -66.6% | 17,276 | -63.5% | 0.01% | -66.7% |
| Q1 2018 | $2,171,000 | -14.1% | 47,276 | -11.3% | 0.02% | -25.0% |
| Q4 2017 | $2,526,000 | 0.0% | 53,276 | 0.0% | 0.02% | 0.0% |
| Q3 2017 | $2,526,000 | -8.5% | 53,276 | 0.0% | 0.02% | -9.1% |
| Q2 2017 | $2,760,000 | +2933.0% | 53,276 | +1266.1% | 0.02% | +2100.0% |
| Q2 2016 | $91,000 | -96.0% | 3,900 | -93.4% | 0.00% | -96.3% |
| Q1 2016 | $2,289,000 | -50.1% | 59,100 | -21.5% | 0.03% | -48.1% |
| Q4 2015 | $4,585,000 | – | 75,300 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |